2 stories mentioning IMNMUpdated 47m ago
Every FINWIRES story that references IMNM, newest first.
Max Rosett, Chief Financial Officer, on June 15, 2026, sold 60,000 shares in Immunome (IMNM) for $1,093,800. Following the Form 4 filing with the SEC, Rosett has control over a total of 54,037 common shares of the company, with 54,037 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1472012/000199407126000004/xslF345X05/form4-06172026_090615.xml
Immunome (IMNM) said Wednesday it has submitted a New Drug Application to the US Food and Drug Administration for varegacestat, an investigational oral treatment for adults with desmoid tumors.The filing is backed by positive Phase 3 RINGSIDE results showing significantly improved progression-free survival versus placebo, with an 84% reduction in the risk of disease progression or death and a 56% objective response rate, the company said.The company added that detailed data from the trial will be presented at the 2026 ASCO Annual Meeting.Shares of Immunome were down 2.7% in Wednesday trading.Price: $23.18, Change: $-0.53, Percent Change: -2.24%
